Associated Papers
Circulating Tumour DNA Is a Biomarker of Response in Angioimmunoblastic T-Cell Lymphoma.
Yannakou CK et al.
International Journal of Molecular Sciences, 2025
Genomic subtypes of non-muscle-invasive bladder cancer: guiding immunotherapy decision-making for patients exposed to aristolochic acid.
Peng Y et al.
Molecular Medicine (cambridge, Mass.), 2025
40247187 (PubMed )
Supplement: 10020_2025_1199_MOESM5_ESM.xlsx › Sheet1
Mutations in Ras homolog family member A in patients with peripheral T-cell lymphoma and implications for personalized medicine.
Hu L et al.
Cancer Biology & Medicine, 2024
Angioimmunoblastic T-cell lymphoma: Novel recurrent mutations and prognostic biomarkers by cell-free DNA profiling.
Zhang C et al.
British Journal of Haematology, 2023
Early detection of T-cell lymphoma with T follicular helper phenotype by RHOA mutation analysis.
Dobson R et al.
Haematologica, 2022
Integrated molecular and pharmacological characterization of patient-derived xenografts from bladder and ureteral cancers identifies new potential therapies.
Lang H et al.
Frontiers in Oncology, 2022
36033544 (PubMed )
Supplement: Table_4.xlsx › Variants
Spatially interacting phosphorylation sites and mutations in cancer.
Huang KL et al.
Nature Communications, 2021
33875650 (PubMed )
Supplement: 41467_2021_22481_MOESM4_ESM.xlsx › TableS1.HybridClusters
Angioimmunoblastic T-cell lymphoma contains multiple clonal T-cell populations derived from a common TET2 mutant progenitor cell.
Yao WQ et al.
The Journal of Pathology, 2020
Select a paper to view details